Hims and Hers Health, the telehealth company that became a pandemic-era market darling, is now facing a securities fraud class action lawsuit stemming from a sweeping federal complaint by the Federal Trade Commission. The lawsuit, filed against the company and certain executives, accuses Hims of serious business misconduct and comes on the heels of a stock crash that wiped out significant shareholder value.
The securities class action cites the July 29, 2026 federal complaint filed against Hims by the FTC, alongside co-plaintiffs the State of Utah and the County of Los Angeles representing California. After an extensive investigation, the Commission contends that Hims engaged in a pattern of deceptive conduct. The class action complaint alleges that the company shared consumers' health information with third-party advertising platforms, a particularly sensitive charge for a healthcare company that repeatedly assured customers it maintained policies and procedures to safeguard their health and personal information.
The allegations go further. The complaint charges that Hims billed consumers for prescriptions almost immediately after they submitted intake forms, despite telling them they would be able to consult with a medical provider to find a treatment that was right for them. In other words, investors were told the company operated a careful, provider-led model, while customers were allegedly being charged before any meaningful medical consultation took place. As a result, the suit argues, the company was exposed to heightened regulatory scrutiny and likely to incur fees and penalties, facts that were not reflected in its public statements.
The market's reaction was swift. On July 29, the day the FTC complaint became public, Hims' stock cratered, and the securities class action now seeks to recover losses for investors who bought shares during the class period of August 4, 2025 through July 29, 2026. The law firm Hagens Berman, which is investigating the claims, has encouraged investors who suffered substantial losses to come forward ahead of a November 2, 2026 lead plaintiff deadline.
The case is a cautionary tale about the telehealth boom's darker side. Hims and Hers built its brand on frictionless access to prescription treatments, from hair loss to weight loss, growing rapidly by lowering the barriers between consumers and medications. Regulators are now asking whether that frictionless model crossed the line into deception, and whether investors were misled about the legal and reputational risks building inside the business.
For the broader digital health sector, the Hims litigation could set important precedents about the use of consumer health data in advertising and the standards for telehealth prescribing. The company has not been found liable, and the allegations remain to be tested in court. But the combination of an FTC enforcement action and a shareholder class action has placed one of telehealth's highest-profile brands in a fight for its credibility.